MA56536A - Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) - Google Patents

Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)

Info

Publication number
MA56536A
MA56536A MA056536A MA56536A MA56536A MA 56536 A MA56536 A MA 56536A MA 056536 A MA056536 A MA 056536A MA 56536 A MA56536 A MA 56536A MA 56536 A MA56536 A MA 56536A
Authority
MA
Morocco
Prior art keywords
hbv
liposomes
hepatitis
virus
administration
Prior art date
Application number
MA056536A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Ian Strickland
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56536A publication Critical patent/MA56536A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
MA056536A 2019-06-20 2020-06-19 Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) MA56536A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863958P 2019-06-20 2019-06-20

Publications (1)

Publication Number Publication Date
MA56536A true MA56536A (fr) 2022-04-27

Family

ID=71833365

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056536A MA56536A (fr) 2019-06-20 2020-06-19 Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)

Country Status (7)

Country Link
US (1) US20220305108A1 (fr)
EP (1) EP3986563A1 (fr)
AU (1) AU2020295807A1 (fr)
CA (1) CA3143631A1 (fr)
MA (1) MA56536A (fr)
TW (1) TW202114732A (fr)
WO (1) WO2020255062A1 (fr)

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
CH621479A5 (fr) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (fr) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE69835761T2 (de) 1997-04-03 2007-09-13 Electrofect As. Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
EP1100579B1 (fr) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Therapie genique par champ electrique pulse visant la peau et les muscles
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2005007196A2 (fr) 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Arn interférant encapsulé dans un lipide
EP1729848B1 (fr) 2004-03-08 2015-04-29 Ichor Medical Systems Inc. Appareil ameliore pour une administration electriquement mediee d'agents therapeutiques
CA2569664C (fr) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans des lipides
PL2409727T3 (pl) 2006-10-17 2019-03-29 Inovio Pharmaceuticals, Inc. Urządzenia elektroporacyjne do elektroporacji komórek u ssaków
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
RU2013104890A (ru) * 2010-07-06 2014-08-20 Новартис Аг Вирионоподобные частицы для доставки самореплицирующихся молекул рнк
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
BR112014004607A2 (pt) 2011-08-31 2017-03-21 Novartis Ag lipossomas peguilados para entrega de rna codificado imunogênico
WO2013126803A1 (fr) 2012-02-24 2013-08-29 Protiva Biotherapeutics Inc. Lipides cationiques trialkylés et leurs procédés d'utilisation
WO2016020538A1 (fr) * 2014-08-08 2016-02-11 Transgene Sa Traitement en association d'un vaccin contre le hbv et d'un anticorps pour traiter des infections à hbv.
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
CA2990202A1 (fr) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Formulations de lipides et de nanoparticules de lipides pour l'administration d'acides nucleiques
NZ739902A (en) 2015-07-31 2022-09-30 Arcturus Therapeutics Inc Multiligand agent for drug delivery
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
KR102535764B1 (ko) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 치료제를 전달하기 위한 장치
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (fr) 2016-12-21 2018-06-28 Payne Joseph E Lipide cationique ionisable pour l'administration d'arn
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018191657A1 (fr) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipides pour administration d'agents actifs
WO2018199338A1 (fr) * 2017-04-27 2018-11-01 国立大学法人広島大学 Molécule d'acide nucléique pour le traitement de l'hépatite b
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20200172472A1 (en) 2017-08-17 2020-06-04 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019051257A2 (fr) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation Méthodes de traitement des infections de type hépatite b

Also Published As

Publication number Publication date
AU2020295807A1 (en) 2022-02-17
WO2020255062A1 (fr) 2020-12-24
EP3986563A1 (fr) 2022-04-27
TW202114732A (zh) 2021-04-16
US20220305108A1 (en) 2022-09-29
CA3143631A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
Chinese Medical Association The guidelines of prevention and treatment for chronic hepatitis B (2019 version)
WO2017027350A3 (fr) Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
MA50278A (fr) Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
WO2018027106A3 (fr) Agent arni contre l'infection par le virus de l'hépatite b
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
MY154683A (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
JP2020531422A5 (fr)
EP3710049A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
WO2017019891A3 (fr) Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
MD20140058A2 (en) Compositions and methods for treating hepatitis C virus
WO2014089296A3 (fr) Dérivés fonctionnalisés de benzamide en tant qu'agents antiviraux contre une infection à vhb
EA201301158A1 (ru) Противовирусные соединения
JP2019511542A5 (fr)
MY191515A (en) Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
SI2968302T1 (en) Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV
NZ628445A (en) Antiviral compounds with a heterotricycle moiety
HRP20150430T1 (hr) Lijeäśenje same virusne infekcije hepatitisa b ili kombinirane s delta virusom hepatitisa te povezanih jetrenih bolesti
MX2019013815A (es) Inhibidor de antigenos de superficie del virus de la hepatitis b.
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
MA56536A (fr) Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)